Company Overview and News

13
Shares drop 1.2%, led by Pushpay and Mercury

19h nzherald.co.nz
New Zealand shares dropped in broad-based selling, led lower by Pushpay Holdings following its $100 million bookbuild, with Mercury New Zealand and Fletcher Building also weakening.
CEN FBU FCREY SPKKY NZTCY SPK NZTCF FRCEF COENY COENF PPSHY FBU CEN

13
Spark leads sharemarket higher

2018-05-28 nzherald.co.nz
New Zealand shares edged higher, led by Spark New Zealand and Arvida Group, while Scales Corp and Fisher & Paykel Healthcare weakened.
KTHDY FBU FCREY SPKKY NZTCY SPK NZTCF FRCEF FTRRF KMD FBU EVO KMD

11
Spark expects annual earnings to fall

2018-05-25 nzherald.co.nz
Spark New Zealand expects annual earnings to fall by as much as 2.5 per cent this year as it brings forward restructuring costs and accelerates its 'Quantum Programme' to transform the country's biggest telecommunications company into the operator with the lowest costs.
NZTCY SPKKY SPK NZTCF QTM

27
Shares up as Comvita, A2 rebound from weakness, Steel & Tube keeps dropping

2018-05-25 nzherald.co.nz
New Zealand shares gained as Comvita and A2 Milk Co recovered from selling, while Air New Zealand and Steel & Tube Holdings fell.
NMR FBU AIR FCREY SPKKY NZTCY SPK NZTCF FRCEF ANZFY AIZ VIL 8604 SKC N33 FBU THL ANZLY NRSCF ANZFF SML

16
Honey products exporter Comvita leads sharemarket down

2018-05-21 nzherald.co.nz
New Zealand shares dropped, led lower by Comvita as its possible takeover failed, with A2 Milk continuing last week's losses and Kiwi Property Group dropping on its earnings.
KTHDY NMR SPKKY NZTCY SPK NZTCF KWIPF KMD 8604 N33 THL NRSCF KMD SML

23
Shares gain as Ryman posts record profit

2018-05-18 nzherald.co.nz
New Zealand shares rose as Goodman Property Trust's joint venture with GIC sold seven buildings in downtown Auckland, and as Ryman Healthcare chalked up another record profit. A2 Milk Co and Comvita fell.
AIA FBU RHCGF FCREY SPKKY NZTCY ZNRGF SPK NZTCF RYM ACKDF FRCEF ZEL AUKNY ZNZ AIA FBU RYHTY MEZ

16
Shares rise, led by A2 and Synlait

2018-05-17 nzherald.co.nz
New Zealand shares rose, led by A2 Milk Co and Synlait Milk while Pushpay fell after annual earnings met its guidance, disappointing some upbeat investors.
BGR WBC SPKKY NZTCY SPK NZTCF WEBNF WBK SKT SYKWF WBC PPSHY VTHPF SKKTY SML

20
A2 tumbles, dragging down stock index

2018-05-16 nzherald.co.nz
New Zealand shares fell as A2 Milk Co disappointed investors with a market update, dragging down partner Synlait Milk.
FBU RHCGF FCREY SPKKY NZTCY SPK NZTCF RYM FRCEF SKT SYKWF FBU RYHTY VTHPF SNZ SKKTY SML

20
Expert: A2 Milk could replace Fletcher Building in key sharemarket index

2018-05-13 nzherald.co.nz
Mark Lister, head of private wealth research at Craigs Investment Partners, said the announcement of Fletcher's place in the MSCI Index is due out today and we will know the result tomorrow.
AIA FBU RHCGF FCREY SPKKY NZTCY SPK NZTCF RYM ACKDF FRCEF AUKNY AIA FBU RYHTY MEZ

34
Shares rise as investors second guess index changes; Fletcher gains

2018-05-08 nzherald.co.nz
New Zealand shares rose, joining a regional rally, as investors predict whether an upcoming MSCI index review will spur major activity next week. Fletcher Building, which could exit the index, gains, while new addition a2 Milk Co fell.
CEN TME TRMEF PYIYY AIR FCREY NZTCF ACKDF ANZFY AUKNY AIZ KMD COENF TME CEN KMD KTHDY AIA FBU WBC SPKKY NZTCY SPK WEBNF WBK FRCEF COENY AIA WBC FBU ANZLY MPP MTPGF ANZFF TDMEY MEZ PFI

15
NZ shares mixed, A2 gains while Gentrack, Spark, bank stocks drop

2018-05-04 nzherald.co.nz
New Zealand shares were mixed, with A2 Milk pulling the index up while Gentrack Group, Spark New Zealand and banking stocks dropped.
WBC SPKKY NZTCY ZNRGF SPK NZTCF WEBNF WBK ZEL ZNZ WBC PPSHY GTK SML

5
Spark sells 50 pct stake in services infrastructure unit to Electra Group

2018-05-03 nzherald.co.nz
Spark New Zealand is selling half of its Connect 8 services infrastructure unit to electricity distributor Electra Group, in a deal which will see Connect 8 take full ownership of Electra's telecommunication's contractor Sky Communications.
VOC VCMMF NZTCY SPKKY SPK NZTCF

30
NZ shares up as A2 leads index

2018-05-02 nzherald.co.nz
New Zealand shares gained, with Gentrack Group hitting a record and electricity companies Mercury New Zealand and Contact Energy gaining.
CEN FCREY NZTCF RYM KMD COENF GNE AOTUF CEN KMD GEL KTHDY FBU WBC RHCGF SPKKY NZTCY SPK WEBNF WBK FRCEF COENY WBC FBU RYHTY GNE GTK MEZ

11
NZ shares up 1%, led by Fisher & Paykel, Kathmandu, Spark

2018-04-27 nzherald.co.nz
New Zealand shares gained, led by Fisher & Paykel Healthcare Corp and Kathmandu in broad-based buying.
KTHDY AIA AIA NZTCY SPKKY SPK NZTCF ACKDF KMD AUKNY MEZ KMD

22
NZ shares gain; Trade Me rises

2018-04-18 nzherald.co.nz
New Zealand shares gained in light trading as Fletcher Building's discounted rights issue and upcoming MSCI New Zealand index review weighed on investors' minds. Trade Me and Metlifecare increased while Comvita dropped.
KTHDY BGR AIA FBU FCREY SPKKY NZTCY SPK NZTCF ACKDF FRCEF AUKNY KMD SKT SYKWF AIA PPSHY FBU SKKTY KMD MEZ SML

Related Articles

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

2018-06-18 - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

PRTO: Proteon Therapeutics Analysis and Research Report

2018-06-11 - Asif

Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...

GALE: Galena Biopharma Analysis and Research Report

2018-06-11 - Asif

Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...

CUSIP: Q8619N107